Indian Journal of Health Sciences and Biomedical Research KLEU

REVIEW ARTICLE
Year
: 2018  |  Volume : 11  |  Issue : 3  |  Page : 207--214

Probiotic use in the management of hypertension: A new era of therapeutic management


Swapnil Purushottam Borse1, Devendra Pratap Singh1, Dilawar Upadhyay2, Vipin Sharma3, Manish A Nivsarkar3 
1 Department of Pharmacology and Toxicology, B. V. Patel Pharmaceutical Education and Research Development Centre; Department of Pharmacology and Toxicology, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India
2 Sun Pharma Advanced Research Company Ltd., Vadodara, Gujarat, India
3 Department of Pharmacology and Toxicology, B. V. Patel Pharmaceutical Education and Research Development Centre, Ahmedabad, Gujarat, India

Correspondence Address:
Dr. Manish A Nivsarkar
B. V. Patel Pharmaceutical Education and Research Development Centre, S. G. Highway, Thaltej, Ahmedabad - 380 054, Gujarat
India

Hypertension (HTN) has become a common chronic medical condition which affects ≥20% of adult population worldwide. HTN is assumed to be a major contributing factor for increasing complication of metabolic syndrome by adding one or more comorbidities such as heart disease, stroke, chronic renal failure, myocardial infarction, blindness, and dementia. HTN is also considered as a lifestyle disorder, and there are mainly two types of HTN, namely primary and secondary. Primary HTN is about 90%–95% of all cases of HTN and it is defined as high blood pressure due to genetic factors and nonspecific lifestyle, while secondary HTN is due to an identifiable cause such as Cushing's syndrome, obesity, and glucose intolerance. However, the exact cause and pathophysiology of HTN is still not clear. On the other hand, human body acts as a host and around 100 trillion bacteria are present in the body which is 10 times more than the number of cells in the human body. Many studies have published the role of microbiome in health and disease. Recent findings have shed light on the important role of microbiota in HTN and its treatment with probiotics (beneficial microbiota to host). Considering this, here, we have summarized and focused on possible interplays between the HTN microbiota, pharmacotherapeutic use of probiotics in HTN, and prospects to increase the degree of therapeutic personalization.


How to cite this article:
Borse SP, Singh DP, Upadhyay D, Sharma V, Nivsarkar MA. Probiotic use in the management of hypertension: A new era of therapeutic management.Indian J Health Sci Biomed Res 2018;11:207-214


How to cite this URL:
Borse SP, Singh DP, Upadhyay D, Sharma V, Nivsarkar MA. Probiotic use in the management of hypertension: A new era of therapeutic management. Indian J Health Sci Biomed Res [serial online] 2018 [cited 2019 Jan 20 ];11:207-214
Available from: http://www.ijournalhs.org/article.asp?issn=2349-5006;year=2018;volume=11;issue=3;spage=207;epage=214;aulast=Borse;type=0